MedTrace Logo

Fenofibrate and Pharmacogenetic Impact in Dyslipidemia

NCT00613613 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2020-01-13

No results posted yet for this study

Summary

The purpose of the study is to learn whether genetics plays a role in predicting response to a commonly used and FDA (Food and Drug Administration) approved medication for lowering triglycerides and cholesterol. The hypothesis: The pharmacogenetics of genes which affect drug metabolism (how the body handles the drug) and drug targets (how the drug acts on the body) influences how a person responds to the lipid lowering medication-fenofibrate.

Conditions

Interventions

DRUG

fenofibrate

Fenofibrate 145mg tablets once daily for 4 weeks

DRUG

fenofibrate

Fenofibrate 145mg tablets once daily for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Robert J. Straka · University of Minnesota

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2013-10-31
Completion
2013-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00613613 on ClinicalTrials.gov